Get the newsletter
IBM · Biotech · Filed Jan 6, 2026 · USPTO published May 14, 2026 · May 14 release

IBM Patents a System That Catches Forgotten Meals and Calculates Insulin Doses

Forgetting to log a meal is one of the most common — and dangerous — mistakes in insulin-dependent diabetes management. IBM's new patent describes a system that notices you ate something even when you didn't tell it you did.

IBM Patent: AI Detects Missed Meals for Insulin Dosing, figure from US 2026/0130627 A1
Figure from the official USPTO publication.
Publication number
US 2026/0130627 A1(US20260130627A1)
Applicant
International Business Machines Corporation
Filed · Published
Jan 6, 2026 · May 14, 2026
Inventors
Paul Joseph Galley, Christian Ringemann, Yannick Klopfenstein, Patrick Lustenberger, Eemeli Leppäaho, Pau Herrero Viñas
Status when we published
Waiting for an examiner
Document
15 claims
US classification
600/301
Parent application
Continuation of PCT/EP2024/069112 (filed Jul 5, 2024)(PCTEP2024069112)

How IBM's system spots a meal you forgot to log

Imagine you're managing Type 1 diabetes with an insulin pump and a continuous glucose monitor (CGM). You grab a sandwich, get distracted, and forget to log the meal or trigger a bolus dose. Your blood sugar spikes — and by the time you notice, you're already in trouble.

IBM's patent describes a smarter system: one that watches your glucose readings in real time, detects the characteristic rise that follows eating, and checks whether you actually told it you had a meal. If no meal was logged, it flags a missed meal event and calculates a recommended insulin dose based on how long ago you ate.

The clever part is the timing adjustment. A bolus given two hours after a meal needs to be calculated differently than one given right after eating. The system factors in that elapsed time so the recommended dose is appropriate for where your body currently is in digesting that meal — not where it was when you first sat down.

How the sensor data flags a missed meal event

The system centers on a continuous analyte sensor — think a CGM patch on your arm transmitting glucose readings every few minutes. Those readings arrive as a time series, and a processor monitors that stream for patterns.

When the processor sees a rapid upward change in glucose levels that crosses a predetermined threshold, it generates a timestamp marking the likely start of a meal. It then checks that timestamp against a log of recorded meal events stored in memory. If there's no matching entry, the system classifies this as a missed meal event — a meal the user consumed but never officially logged.

From there, the system calculates a recommended medication bolus (the dose of insulin to administer). Crucially, this calculation incorporates the length of time elapsed between the missed meal timestamp and the current moment. This is important because insulin timing relative to carbohydrate absorption is highly nonlinear — a late correction dose needs to account for how much glucose has already been processed.

Finally, an output message is generated — likely a notification on a paired device — telling the user what dose is recommended. The patent doesn't specify how the user acts on this (manual injection, pump command, etc.), keeping the architecture flexible.

What this means for diabetes management tech

For the roughly 8 million Americans using insulin, missed boluses are a leading cause of hyperglycemic episodes. Current closed-loop insulin systems (sometimes called artificial pancreas systems) can automate basal insulin delivery but still rely heavily on the user manually announcing meals. IBM's approach fills that gap by making meal detection passive and automatic, reducing the cognitive load on the user.

This patent sits in a competitive space alongside CGM makers like Dexcom and Abbott, and insulin pump companies like Tandem and Medtronic. IBM doesn't make medical hardware, so this filing likely signals interest in the software and AI layer of diabetes management — possibly as a platform or licensing play rather than a consumer device.

Source: US 2026/0130627 A1 at the USPTO (PDF). Full patent text and figures are in the official publication.

Get our take in your Top Stories

Liked this breakdown? Add Patentlyze as a preferred source on Google, and our plain-English take shows up more often in your Top Stories the next time IBM patent news breaks.

There are more where this came from

We read every patent application Big Tech publishes and send you the ones worth knowing. Plain English, free, every week.